Memaneine - instructions for use, dose, side effects, contraindications

Memantine - a drug that improves brain metabolism, used to treat dementia; has a muscle relaxant effect. Has nootropic, cerebrozodilating, antihypoxic, neuroprotective and psychostimulating action.

Pharmacodynamics

Being a noncompetitive antagonist, N-methyl-D-aspartate (NMDA) -receptors, has a modulating effect on the glutamatergic system. It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the process of nerve impulse transmission, improves cognitive processes, memory and learning ability, increases daily activity.

Pharmacokinetics:

Suction and distribution

After oral administration memantine quickly and completely absorbed from the digestive tract. C_max is achieved within 2-6 hours.

With normal renal function, no cumulation of memantine was observed.

Excretion

Elimination proceeds biphasic. T_1/2 on the average in the first phase of 4-9 hours, in the second phase - 40-65 hours. It is excreted mainly by the kidneys (75-90%).

Indications:Dementia of the Alzheimer's type of moderate and severe degree.

Contraindications:Pronounced disorders of kidney and liver function; pregnancy; breastfeeding, hypersensitivity to the drug, children under 18 years (due to insufficient data).

Carefully:With caution appoint the drug with thyrotoxicosis, epilepsy, convulsions (including in the history), myocardial infarction, heart failure.

Pregnancy and lactation:Memanneine is contraindicated in pregnancy.If you need to use Memaneurin during lactation, you should decide whether to stop breastfeeding. In experimental studies conducted on animals, it was shown that Memaneirin does not have embryotoxic and teratogenic effects.

Dosing and Administration:

Install individually. Begin the treatment recommended with the appointment of minimally effective doses.

The daily dose is evenly divided into several doses during the day. The drug should be taken with food, the last dose is recommended to take before dinner.

Adults prescribe the drug

during the first week of therapy at a dose of up to 5 mg / day (12 drops),

during the 2nd week - in a dose up to 10 mg / day (24 drops),

during the third week - 15-20 mg / day (36-48 drops).

If necessary, further weekly increase in the dose of 10 mg to achieve a daily dose of 30 mg (72 drops).

The estimated value of the maintenance dose is 10-20 mg / day (24-48 drops).

Side effects:Adverse reactions are classified according to clinical manifestations (in accordance with the damage of certain organ systems) and frequency of occurrence: very often (≥1 / 10), often (≥1 / 100 to <1/10),not often (≥1 / 1,000 to <1/100), rarely (≥1 / 10,000 to <1 / 1,000), very rarely (<1 / 10,000), frequency not established (current prevalence data are not available) .

From the side of thein general - general adverse reactions	Often	Headache
From the side of thein general - general adverse reactions	Rarely	Fatigability
Infections	Rarely	Fungal infections
Mental disorders	Often	Drowsiness
	Infrequently	Depression
	Rarely	Confusion, hallucinations¹
	Frequency not set	Psychological reactions, suicidal thoughts, suicide attempts2
Hcrochetingno-vascular system	Infrequently	Heart failure
Hcrochetingno-vascular system	Rarely	Hypertension, venous thrombosis / thrombosisemboLiya
Respiratory system disorders	Often	Dyspnea
Gastrointestinal Mr.caving	Often	Constipation
	Rarely	Nausea, vomiting
	Frequency not set	Pankreatitis²
Disorders from the liver and fелчевыводящих ways	Often	Phigh liver function samples
Impaired immunitybutth system	Often	Hypersensitivity reactionstthe
	Often	Disturbance, dizziness
	Rarely	Violation of gait
	Rarely	Convulsions

¹Hallucinations were observed, mainly, in patients with Alzheimer's disease at the stage of severe dementia

²There are separate reports of the occurrence of these adverse reactions when the drug is used in clinical practice (data obtained after the appearance of the drug on sale).

Unwanted reaction

Agranulocytosis, leukopenia (including neuropathy), pancytopenia, thrombocytopenia, thrombocytopenic purpura, hepatitis, acute renal failure, Stevens-Jones syndrome.

Overdose:

Symptoms: there may be an increase in the manifestations of the described side effects.

Treatment: gastric lavage, reception of activated charcoal; if necessary, conduct symptomatic therapy.

Interaction:When used simultaneously with L-dopa preparations, dopamine agonists, anticholinergic agents, the effect of the latter may be enhanced. With simultaneous use with barbiturates, neuroleptics, the effect of the latter may decrease. When combined, the effect of dantrolene or baclofen can be altered (enhanced or decreased), so the doses of the drugs should be selected individually. Simultaneous administration with amantadine, ketamine and dexamethophan should be avoided.Possible increase in plasma levels of cimetidine, procainamide, kinidin-on, kinin and nicotine with simultaneous administration with memantine. It is possible to reduce the level of hydrochlorothiazide when taken concomitantly with memantine.

Special instructions:

Patients in the elderly are advised to prescribe the drug in the form of drops.

The optimal dose is achieved gradually, with increasing doses every week.

For patients with impaired renal function, the dosing regimen is set individually, depending on the clinical effectiveness, under the control of kidney function during treatment.

Effect on the ability to drive transp. cf. and fur:With caution apply during work drivers of vehicles and people whose profession is associated with increased concentration of attention.

Form release / dosage:Drops for ingestion 10 mg / ml.

Packaging:To 50, 100 ml in bottles of dark glass with plugs-droppers plastic and caps screwed plastic with the control of the first opening or without it in an individual pack of cardboard with instructions for medical use.

Storage conditions:

In the dark place at a temperature of no higher than +25 ° C.

Keep out of the reach of children.

Shelf life:2 years. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LP-000660

Date of registration:28.09.2011 / 29.09.2016

Expiration Date:Unlimited

The owner of the registration certificate:BIS, CJSCBIS, CJSC Russia

Manufacturer: & nbsp

BIS, CJSC Russia

Information update date: & nbsp24.04.2018

Illustrated instructions

Instructions

Memaneirin (Memaneurin)